PointState Capital LP Cuts Position in Natera, Inc. (NASDAQ:NTRA)

PointState Capital LP trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 27.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 569,252 shares of the medical research company's stock after selling 213,286 shares during the period. Natera comprises about 1.6% of PointState Capital LP's portfolio, making the stock its 21st biggest position. PointState Capital LP owned 0.43% of Natera worth $90,113,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its stake in Natera by 50.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock valued at $104,000 after purchasing an additional 220 shares during the last quarter. SeaBridge Investment Advisors LLC purchased a new position in Natera in the fourth quarter valued at approximately $2,894,000. SYM FINANCIAL Corp acquired a new stake in shares of Natera in the fourth quarter valued at approximately $256,000. KBC Group NV boosted its holdings in shares of Natera by 753.8% in the fourth quarter. KBC Group NV now owns 27,551 shares of the medical research company's stock valued at $4,361,000 after acquiring an additional 24,324 shares during the period. Finally, Steward Partners Investment Advisory LLC boosted its holdings in shares of Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after acquiring an additional 332 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Price Performance

Natera stock opened at $151.34 on Thursday. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The business has a fifty day moving average of $148.12 and a two-hundred day moving average of $156.12. The company has a market cap of $20.46 billion, a P/E ratio of -85.99 and a beta of 1.79.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The firm had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm's quarterly revenue was up 36.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.56) EPS. As a group, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group increased their price objective on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Barclays increased their price objective on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. BTIG Research reaffirmed a "buy" rating on shares of Natera in a report on Friday, February 28th. Royal Bank of Canada initiated coverage on Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target for the company. Finally, StockNews.com raised Natera from a "sell" rating to a "hold" rating in a report on Friday, May 9th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and an average target price of $181.82.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 87,272 shares of Natera stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the completion of the sale, the chief executive officer now owns 203,354 shares in the company, valued at approximately $29,160,963.60. This trade represents a 30.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 2,206 shares of Natera stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $152.18, for a total value of $335,709.08. Following the completion of the sale, the insider now owns 139,280 shares of the company's stock, valued at $21,195,630.40. This trade represents a 1.56% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 152,436 shares of company stock worth $22,019,079. 7.60% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.